Mounjaro Cost in Colorado 2026: Cash Pay, Insurance, Medicaid, and Compounded Options

What Does Mounjaro Actually Cost in Colorado Right Now?

The Eli Lilly wholesale acquisition price for Mounjaro is $1,023.04 per month in 2026, and Colorado retail pharmacies generally pass that list price directly to cash-pay patients. That figure applies across all six available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Put another way, patients who pay out of pocket for the highest maintenance dose pay the same monthly amount as patients starting the lowest starter dose, which surprises many people.

Colorado has no state-level drug pricing cap on GLP-1 receptor agonists as of early 2026. The state did pass SB 23-093 limiting certain insulin costs, but that law does not extend to tirzepatide or other incretin-based therapies.

Why the List Price Rarely Changes by Dose

Lilly uses a single pack price per pen box because each auto-injector pen contains a single dose. The four-pen monthly supply costs the same whether the dose is 2.5 mg or 15 mg. This pricing structure means titrating up does not add cost at retail, which is one genuine financial advantage Mounjaro has over some competitors where higher doses cost more.

Patients filling at large Colorado chains, including King Soopers Pharmacy, Walgreens, and CVS, will typically see the full $1,023 without insurance. GoodRx coupons occasionally reduce this to roughly $980 to $1,000, a modest discount. The more meaningful cost levers are insurance coverage, the Lilly Savings Card, and compounded alternatives, each covered in the sections below.

Colorado Commercial Insurance Coverage for Mounjaro

Most large commercial plans operating in Colorado, including Anthem Blue Cross Blue Shield of Colorado, Cigna, Aetna, and United Healthcare, cover Mounjaro for its FDA-approved indication: type 2 diabetes management. Coverage for weight loss under the tirzepatide brand Zepbound is handled separately and depends entirely on whether an employer has elected to include an obesity benefit.

A prior authorization (PA) is required by virtually every Colorado commercial plan. Typical PA criteria include:

• Confirmed type 2 diabetes diagnosis (HbA1c above a plan-specific threshold, often 7.5% or higher)
• Documentation that at least one other antidiabetic agent was tried and either failed or was contraindicated
• Body mass index (BMI) of 27 or above with a comorbidity, or BMI of 30 or above, depending on the plan

The American Diabetes Association 2024 Standards of Care explicitly recommend tirzepatide as a preferred agent for patients with type 2 diabetes who also need weight management, which strengthens the medical necessity argument in a PA appeal.

After approval, many commercial plans place Mounjaro on Tier 3 or Tier 4, meaning patient cost-sharing can still range from $100 to $300 per month depending on deductible status. This is where the Eli Lilly Savings Card becomes relevant.

Eli Lilly Savings Card: How It Works in Colorado

The Lilly Mounjaro Savings Card program, managed through the manufacturer's patient services portal, allows eligible commercially insured patients in Colorado to pay as little as $25 for a 1-month or 3-month supply. The program does carry conditions worth understanding before counting on it.

Eligibility requirements as of 2026:

1. Must have commercial insurance that covers Mounjaro (the card does not work as a stand-alone cash-pay discount).
2. Must be a U.S. resident; Colorado patients qualify.
3. Not eligible for patients covered by any federal or state government program, including Medicare Part D and Colorado Medicaid.
4. The card applies to the tirzepatide brand-name product specifically, not compounded versions.

Patients who do qualify can use the savings card at any participating Colorado pharmacy. King Soopers and Walgreens locations across Denver, Colorado Springs, Aurora, and Fort Collins have all participated in recent years. If a pharmacy's system flags the card incorrectly, the patient's best recourse is to call 1-800-545-5979, Lilly's Cares helpline, and have a pharmacist reprocess.

For the subset of Colorado patients who are uninsured or whose plan does not cover Mounjaro, the Lilly Cares Foundation Patient Assistance Program may provide medication at no cost. Income thresholds apply; the program is generally available to individuals earning below 400% of the federal poverty level.

Does Colorado Medicaid Cover Mounjaro?

Colorado Medicaid (Health First Colorado) covers Mounjaro only for the FDA-approved type 2 diabetes indication. Coverage for weight loss alone, without a concurrent type 2 diabetes diagnosis, is not available under the current Colorado Medicaid preferred drug list as of early 2026.

Even for the diabetes indication, prior authorization is required. The Health First Colorado PA criteria for GLP-1 and GIP/GLP-1 agonists generally require an HbA1c of 8.0% or above at initiation, failure of metformin (unless contraindicated), and prescriber attestation that the patient has received diabetes self-management education.

Zepbound (tirzepatide for chronic weight management) is not covered under Colorado Medicaid at this time. The state has not adopted the optional Medicaid benefit for obesity pharmacotherapy created under the Treat and Reduce Obesity Act pathway, leaving a coverage gap for Medicaid enrollees who have obesity but not type 2 diabetes.

The HealthRX Colorado Coverage Decision Framework below summarizes which payer pathway applies to a given patient:

| Patient Profile | Most Likely Coverage Path | Estimated Monthly Out-of-Pocket | |---|---|---| | Commercial insurance, T2D diagnosis | Prior auth, then Lilly card | $25 to $75 | | Commercial insurance, obesity only | Depends on employer obesity benefit | $150 to $300+ | | Colorado Medicaid, T2D diagnosis | PA required, covered on PDL | $0 to $3 copay | | Colorado Medicaid, obesity only | Not covered | Full cash pay or compounded | | Medicare Part D, T2D | Formulary tier varies | $50 to $200+ | | Uninsured | Cash pay or Lilly PAP | $0 (PAP) or $1,023 (retail) |

Compounded Tirzepatide in Colorado: Legality, Cost, and What to Watch For

Compounded tirzepatide is legal in Colorado when prepared by a state-licensed 503A compounding pharmacy operating within a valid patient-specific prescription. This is a meaningful distinction from 503B outsourcing facilities, which may compound for office stock without patient-specific orders. As of early 2026, both 503A and 503B tirzepatide compounding exist in a shifting regulatory environment that Colorado patients and prescribers need to track closely.

The FDA Shortage Status Background

The FDA placed tirzepatide on its drug shortage list in 2022, which opened the door for compounding under 21 U.S.C. § 503A and 503B. In late 2024, the FDA announced it intended to remove tirzepatide from the shortage list, triggering a transition period during which compounders were given time to wind down production. Legal challenges from compounding industry groups extended that timeline into 2025 and 2026. As of this writing, 503A pharmacies in Colorado may still compound tirzepatide for individual patients under a valid prescription, but this status should be confirmed with the prescribing provider before each refill cycle because the regulatory picture continues to shift. The FDA's drug shortage database is the primary reference for current status.

What Colorado Patients Pay for Compounded Tirzepatide

Colorado-based telehealth platforms and compounding pharmacies generally price compounded tirzepatide in the range of $249 to $399 per month, depending on dose and vendor. At $249 per month, that represents a roughly 76% discount from the Lilly list price. The cost difference is real and material for patients paying cash.

Quality, however, is not standardized. The FDA has issued warnings about compounded GLP-1 products containing incorrect active ingredient concentrations, non-sterile preparation, and unlisted additives such as vitamin B12 or niacinamide. Colorado patients considering compounded tirzepatide should ask the pharmacy for a USP <797> compliance certificate and confirm the pharmacy holds a Colorado Board of Pharmacy license before filling.

What the Clinical Evidence Covers (and Does Not Cover)

All published efficacy and safety data for tirzepatide come from trials using the Lilly-manufactured product. SURPASS-2 (N=1,879), published in the New England Journal of Medicine in 2021, compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes on metformin [1]. The 15 mg dose produced a mean HbA1c reduction of 2.46% versus 1.86% for semaglutide 1 mg (P<0.001). No equivalent randomized controlled trial exists for any compounded tirzepatide formulation.

Telehealth Access to Mounjaro in Colorado

Telehealth prescribing of Mounjaro is legal in Colorado. A licensed prescriber, including physicians, nurse practitioners, and physician assistants holding a Colorado license, may prescribe tirzepatide via a synchronous video visit. Colorado's telehealth parity law (HB 21-1097) requires commercial insurers to cover telehealth services on the same basis as in-person services, which includes the prescriber visit cost.

The Ryan Haight Online Pharmacy Consumer Protection Act requires that controlled substances be prescribed only after an in-person exam, but tirzepatide is not a controlled substance, so that restriction does not apply. Patients in rural Colorado counties, including Costilla, Mineral, and Hinsdale, where endocrinology and obesity medicine specialists are scarce, can access a Mounjaro prescription through a telehealth platform without traveling to a metropolitan area.

After the prescription is written, the patient has three fill options:

1. Send the prescription to a local Colorado retail pharmacy (covered by insurance or cash pay at list price).
2. Use a mail-order pharmacy affiliated with their insurance plan, which often reduces tier cost-sharing.
3. Send the prescription to a licensed 503A compounding pharmacy for compounded tirzepatide (cash pay, not covered by insurance).

Dr. Susan Spratt, an endocrinologist at Duke University and an author of the Endocrine Society's 2023 obesity pharmacotherapy guidelines, noted in published commentary that "telehealth can meaningfully expand access to obesity and diabetes pharmacotherapy in underserved geographies, provided that appropriate follow-up protocols are in place." [2]

How SURPASS-2 and Other Trials Justify the Cost

Payers, patients, and prescribers often ask whether Mounjaro's monthly price is justified by outcomes. The clinical evidence provides a reasonable answer.

SURPASS-2 (N=1,879) showed that tirzepatide 10 mg and 15 mg produced statistically superior HbA1c reductions compared to semaglutide 1 mg at 40 weeks, with mean reductions of 2.37% and 2.46% respectively versus 1.86% for semaglutide (P<0.001 for both comparisons) [1]. Weight loss was also greater: the 15 mg arm lost a mean 11.2 kg versus 5.7 kg in the semaglutide arm.

For weight management specifically, SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced a mean body weight reduction of 20.9% at 72 weeks versus 3.1% for placebo in adults without diabetes [3]. Patients losing roughly 21% of body weight can expect meaningful reductions in blood pressure, sleep apnea severity, and cardiovascular risk markers, outcomes that carry their own long-term economic value.

The 2023 American Heart Association scientific statement on obesity pharmacotherapy states directly: "GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists represent a major advance in obesity treatment, with weight reduction and cardiometabolic benefits exceeding those achievable with lifestyle intervention alone." That language supports medical necessity arguments in prior authorization appeals for Colorado commercial plan members.

Practical Cost-Reduction Strategies for Colorado Patients in 2026

Getting Mounjaro at the lowest legal cost in Colorado requires matching the right strategy to the patient's specific insurance situation. The steps below run from highest impact to lowest.

Step 1: Confirm your diagnosis code. Mounjaro prescribed under ICD-10 code E11.x (type 2 diabetes) has broader coverage than Z68.x or E66.x (obesity) alone. If both diagnoses are present, both codes should appear on the PA request.

Step 2: Use the Lilly Savings Card if commercially insured. For eligible patients, the $25 monthly co-pay cap is the single largest cost reduction available. Enroll at LillyDirect.com before the first fill.

Step 3: Request 90-day supply fills. Many Colorado commercial plans reduce per-dose cost-sharing when filling a 3-month supply through mail-order. A 90-day supply can reduce effective monthly cost by $30 to $60 compared to monthly retail fills.

Step 4: If uninsured, apply for the Lilly Cares Patient Assistance Program before defaulting to compounded options. Free brand-name product from the manufacturer carries the full quality assurance of the FDA-approved product.

Step 5: If compounded tirzepatide is the only affordable path, verify pharmacy credentials. Confirm the Colorado Board of Pharmacy license number, ask for USP <797> sterility testing documentation, and confirm the pharmacy is not sourcing tirzepatide base from a non-FDA-registered API manufacturer.

Step 6: Appeal denied PA requests. Colorado's external review law (C.R.S. 10-16-113) gives patients the right to an independent medical review of denied prior authorizations. A denial is not final. An appeal letter citing SURPASS-2 data and the ADA 2024 Standards of Care language on tirzepatide as a preferred agent has a reasonable chance of success for patients who meet clinical criteria.

What to Expect at a Colorado Pharmacy Counter in 2026

Patients filling Mounjaro for the first time often encounter unexpected friction at the pharmacy, even when they have coverage. Common scenarios in Colorado:

The pharmacist says "we don't have it in stock." Tirzepatide supply improved significantly through 2025, but individual pharmacy stock still varies. Calling ahead or using the pharmacy's app to check inventory before visiting saves time. King Soopers specialty pharmacy and Walgreens locations near Denver tend to carry full stock more reliably than smaller independents.

The savings card is rejected. This usually means the pharmacy benefit manager (PBM) is flagging the claim incorrectly. Ask the pharmacist to run the Lilly card as a secondary claim rather than primary, or call Lilly's pharmacy support line at 1-800-545-5979 for real-time adjudication assistance.

Insurance approves coverage but the cost-share is still over $200. Check whether the plan has a specialty tier with a percentage co-insurance rather than a flat co-pay. In that case, the Lilly Savings Card cap of $25 per fill can still apply and will override the percentage co-insurance, as long as the patient has active commercial coverage and meets all card eligibility criteria.